文献速递免疫规划传染病防控与疫情报告

Vero细胞生产黄热病毒纯化用于灭活疫苗制备

Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture.
PubMed 文献 · Vaccine · 2019-04-30

黄热病在非洲和南美洲热带地区流行,超过9亿人面临风险,现有鸡胚减毒疫苗存在产能限制和罕见致命不良事件。Bio-Manguinhos/FIOCRUZ在无血清Vero细胞生物反应器中生产17DD病毒,经阴离子交换膜吸附器和多模式树脂两步层析纯化及β-丙内酯灭活,病毒总回收率52.7%,残留DNA和宿主细胞蛋白水平符合疫苗要求。

要点

  • 阴离子交换膜吸附器捕获病毒回收率80.2±4.8%,残留DNA 1.3±1.6 ng/dose,符合WHO<10 ng/dose标准
  • 多模式树脂第二步将宿主细胞蛋白降至345±25 ppm,病毒回收率65.7±4.8%
  • 两步层析总病毒回收率52.7%,纯化样品中56 kDa包膜蛋白占鉴定蛋白96.7%

核心结论

  • 两步层析纯化工艺可用于灭活黄热疫苗的病毒纯化,残留DNA符合WHO标准,宿主细胞蛋白显著降低。

研究设计与样本

  • 本研究在无血清Vero细胞生物反应器中生产17DD黄热病毒,经阴离子交换膜吸附器和多模式树脂两步层析纯化,并采用β-丙内酯灭活。

主要发现

  • 阴离子交换膜吸附器捕获步骤病毒回收率80.2±4.8%,残留DNA水平1.3±1.6 ng/dose。
  • 多模式树脂步骤病毒回收率65.7±4.8%,宿主细胞蛋白降至345±25 ppm。
  • 两步层析总病毒回收率52.7%。
  • SDS-PAGE显示56 kDa条带,与病毒包膜蛋白E一致,占鉴定蛋白96.7%;Western blot显示单一条带确认样品身份。

关键数值与推荐

  • 残留DNA水平1.3±1.6 ng/dose,符合WHO推荐<10 ng/dose。
  • 宿主细胞蛋白水平345±25 ppm。
  • 总病毒回收率52.7%。

临床怎么用

  • 该纯化工艺可为灭活黄热疫苗的制备提供候选方案,需进一步评估其规模化可行性和疫苗免疫原性。

局限性

  • 本研究仅报告纯化工艺参数,未涉及纯化病毒的免疫原性或保护效力数据。
  • 宿主细胞蛋白水平虽降低至345±25 ppm,但未说明是否满足人用疫苗的具体标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Yellow fever (YF) is a high-lethality viral disease, endemic in tropical regions of South America and Africa, with a population of over 900 million people under risk. A highly effective attenuated vaccine, produced in embryonated eggs, has been used for about 80 years. However, egg-based production limits manufacturing capacity, and vaccine shortage led to the emergency use of a fractional dose (1/5) by the WHO in an outbreak in Africa in 2016 and by Brazilian authorities during an outbreak in 2018. In addition, rare but fatal adverse events of this vaccine have been reported since 2001. These two aspects make clear the need for the development of a new vaccine. In an effort to develop an inactivated YF vaccine, Bio-Manguinhos/FIOCRUZ started developing a new vaccine based on the production of the attenuated 17DD virus in serum-free conditions in Vero cells propagated in bioreactors, followed by chromatography-based purification and β-propiolactone inactivation. Virus purification was studied in this work. Capture was performed using an anion-exchange membrane adsorber (Sartobind® Q), resulting in a virus recovery of 80.2 ± 4.8% and a residual DNA level of 1.3 ± 1.6 ng/dose, thus in accordance with the recommendations of the WHO (<10 ng/dose). However, the level of host cell proteins (HCP) was still high for a human vaccine, so a second chromatography step was developed based on a multimodal resin (Capto™ Core 700). This step resulted in a virus recovery of 65.7 ± 4.8% and decreased HCP levels to 345 ± 25 ppm. The overall virus recovery in these chromatography steps was 52.7%. SDS-PAGE of the purified sample showed a band with molecular mass of 56 kDa, thus consistent with the virus envelope protein (E) and corresponding to 96.7% of identified proteins. A Western blot stained with an antibody against the E protein showed a single band, confirming the identity of the sample.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pato TP, Souza MCO, Mattos DA, et al. Purification of yellow fever virus produced in Vero cells for inactivated vaccine manufacture. Vaccine. 2019. PMID: 31047674. doi:10.1016/j.vaccine.2019.04.077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。